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Abstract  
Background: Socioeconomic inequality challenges population-level implementation of 
health interventions. We investigated differences by educational level in clinical, 
virological and immunological responses to combined Antiretroviral Treatment (cART) 
in HIV-positive men and women in COHERE, a European collaboration. 
Methods: Data were pooled from 15 cohorts in eight countries of patients initiating 
cART in 1996-2013 with data on educational level categorized in UNESCO/ISCED 
classifications. Kaplan-Meier curves, Cox and piecewise linear mixed models were 
used.  
Results: Of 24,069 HIV-positive patients, 9% had not completed primary education, 
32% had completed primary, 44% secondary, and 15% tertiary education. Overall, 21% 
were women, who were over-represented in lower educational strata. During 132,507 
person-years of follow-up, 1,081 individuals died; cumulative mortality decreased with 
higher educational level (p<0.001). Over 122,765 person-years, new AIDS events or 
death occurred in 2,598 individuals; differences by education were more marked than 
for death alone (p<0.001). Virological response was achieved by 67% of patients 
without completed basic education, 85% with completed primary education, 82% with 
secondary, and 87% with tertiary (p<0.001). Patients with higher education had higher 
CD4-count at cART initiation and at each time after cART but rate of CD4-count 
recovery did not differ. Differences in mortality and clinical responses were similar for 
men and women and were not entirely explained by delayed HIV diagnosis and late 
cART initiation. 
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Conclusions: HIV-positive patients with lower educational level had worse responses 
to cART and survival in European countries with universal healthcare. To maximize the 
population impact of cART, Europe needs to decrease the socioeconomic divide. 
Keywords: HIV; Mortality; Socioeconomic Factors; Inequality; Cohort Studies  
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INTRODUCTION 
Even in settings with universal healthcare access, socioeconomic inequality poses a 
challenge for implementing healthcare interventions at the population level. 
Socioeconomic gradients in morbidity and mortality in men and women are well 
described in the general population (1-3). In HIV-positive persons, socioeconomic 
inequalities have been associated with poorer short-term immunological and virological 
response to combined Antiretroviral Treatment (cART) as well as worse clinical 
outcomes (4-15).  
A large collaboration of HIV cohort studies, the Collaboration of Observational HIV 
Epidemiological Research in Europe (COHERE), has recently reported inequalities by 
educational level; a proxy for socioeconomic status, in HIV testing rates and cART 
initiation in European countries. In these countries with universal access to health care, 
the study highlighted gender differences (15). Individuals with lower educational level, 
particularly men, were more likely to present late, with advanced HIV disease, and 
subsequently were more likely to initiate cART at later stages (15). In cohort studies in 
France, educational level, employment status, and other socioeconomic variables were 
associated with mortality (5-6). Educational level predicts all-cause mortality in HIV-
positive persons in countries with and without universal health care systems (7-11), 
although no clear association was evident in Switzerland (12-13). 
Few of these studies compared the effects of socioeconomic variables for men and 
women separately. Indeed, since socioeconomic position may be a poorer predictor of 
health outcomes in women than in men (16), and the number of women in HIV cohort 
studies is often lower, potential gender differences are often overlooked. In this study, 
we build on our previous findings (15) and hypothesize that inequalities by educational 
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level persist among patients after treatment initiation, and that impaired response to 
cART also varies by gender. Our objectives were thus to investigate differences by 
educational level in virological and immunological response to cART, as well as 
incidence of all-cause mortality and new AIDS-defining events in HIV-positive men 
and women in COHERE data from 1996 to 2013. 
METHODS 
Study design, setting and participants 
COHERE (www.cohere.org) is a collaboration of 40 observational cohorts of HIV-
positive persons from 32 European countries within the EuroCoord Network of 
Excellence (www.eurocoord.net). In our analyses we included data from the 15 cohorts 
in eight European countries (Austria, France, Germany, Greece, Italy, Spain, 
Switzerland, and The Netherlands) that collect information on the educational level of 
HIV-positive patients.  
Each cohort submitted data in a standardised format (the HIV Collaboration Data 
Exchange Protocol, http://www.hicdep.org) to coordinating  centres at the Copenhagen 
HIV Program, Denmark, or the Institut de Santé Publique, d’Epidémiologie et de 
Développement (Bordeaux School of Public Health), Bordeaux, France. The Regional 
Coordinating Centres ensured that strict quality assurance guidelines were adhered to, 
checked the plausibility of data, and removed duplicate records. Data were pooled in the 
COHERE in EuroCoord 2014 merger, completed in September 2014. One of the 
cohorts included in the analysis did not submit to the 2014 merger (ANRS CO3-
Aquitaine); its submission from the previous year (2013) was used in the 2014 merger.  
Patients recruited between 1
st
 January, 1996 and 31
st
 December, 2013 were included if 
they were 18 years or older and belonged to cohorts that systematically collected data 
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on educational level, initiated cART while antiretroviral-naïve, and had at least one 
CD4 count and one HIV-RNA measurement recorded in the six months before and the 
six months after starting cART.  Patients were followed in each cohort according to 
routine clinical practice.  
 
Variables and definitions  
Data included age, sex, geographical origin, HIV-1 transmission category, use of cART 
(type of regime and start and stop dates), CD4 cell counts, and plasma HIV-RNA over 
time with dates of measurements, prevalent and incident AIDS defining conditions, 
dates of diagnoses, and vital status. cART was defined as a combination of either ≥3 
drugs from ≥2 classes, or ≥3 nucleoside reverse-transcriptase inhibitors, at least one of 
which was tenofovir or abacavir. Death and date of death were ascertained by reviewing 
charts or crosschecking with mortality registers. Further information on COHERE is 
available at www.cohere.org.  
In 2012, EuroCoord investigators standardised data on educational level across cohorts. 
Maximum attained level of education was defined and classified according to the 
UNESCO/ISCED standard as no or incomplete primary (ISCED 0), primary (ISCED 1 
and 2), secondary (ISCED 3 and 4), and tertiary (ISCED 5 and 6) based on data on 
education systems and reforms available from the European Encyclopaedia on National 
Education Systems (eacea.ec.europa.eu/education/eurydice/eurypedia_en.php).  
Outcomes 
Outcomes were time from cART initiation to i) death from any cause; ii) a new AIDS-
defining event or death from any cause; iii) virological suppression, defined as the first 
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of two consecutive HIV-RNA measurements <400 copies/mL, and an increase in CD4 
cell count in the first 6 years of cART.  
Statistical analyses 
For mortality, clinical, and virological outcomes, we explored differences by 
educational level using Kaplan-Meier curves and log-rank tests. Hazard ratios (HRs) for 
the outcomes of interest were estimated using Cox proportional hazards models 
stratified by cohort.  
Follow-up began at the start of cART and ended at the date the patient was last known 
to be alive, death, or the date of administrative censoring, whichever occurred first. We 
assumed that patients remained on therapy once cART was initiated, ignoring 
subsequent treatment changes or interruptions.   
We used piecewise linear mixed models with a change in slope at 6 months after cART 
to compare trajectories of CD4 counts on the square root scale between educational 
groups over the first 6 years of cART. We determined the change point based on 
exploratory analyses using nonlinear models (17). To test for differences in rate of CD4 
count recovery after cART, we included an interaction term between educational level 
and slope before and after the change point.  
We chose, a priori, to adjust all models for the following potential confounding 
variables: sex; age at cART initiation; calendar period of cART initiation (<2001, 2001-
2004 and 2005-2008, 2009-2013); transmission category (men having sex with men 
[MSM], heterosexual, injecting drug users [IDU], other/unknown); country of 
origin/country of birth (Europe, non-European, unknown); pre-cART HIV-RNA on the 
log10 scale; pre-cART AIDS diagnosis; and initial class type of regime (non-nucleoside 
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reverse transcriptase inhibitors [NNRTI], protease inhibitors PI], and others). We also 
adjusted models for clinical and virological response outcomes by pre-cART CD4 count 
category (<200, 200-349, 350, 499, ≥500 cells/mm3). Moreover, we described 
differences by broad cohort geographical areas defined as Western and Northern Europe 
(Austria, France, Germany, the Netherlands, and Switzerland), and Southern Europe 
(Greece, Italy, and Spain). These analyses were descriptive and not adjusted for 
potential confounders. Finally, we described differences by educational level in the 
proportion of patients lost to follow-up. This was defined as the proportion of living 
individuals who had no medical encounter in the 18 months prior to the median last 
clinical encounter date for the corresponding cohort.    
Sensitivity analyses 
The main analyses excluded patients whose educational level was unknown. In 
sensitivity analyses we imputed missing data on education by multiple imputation using 
chained equations, assuming the data were missing at random (18). Twenty imputed 
data sets were generated, separately analyzed, and combined using Rubin’s rule. We 
also used an extreme scenario analysis and assumed that data from patients with 
unknown educational level were not missing at random and corresponded to i) primary 
education, ii) secondary education, or iii) tertiary education. Since younger individuals 
may not yet have finished their education, we restricted analyses to patients aged ≥25 
years at cART initiation.  
We used Stata statistical software, version 12 (StataCorp) for all analyses.  
Ethics 
All cohorts participating in COHERE adhere to local ethical standards, which extend to 
this study.  
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RESULTS 
A total of 35, 063 individuals met eligibility criteria. The main analyses were based on 
the 24, 069 individuals with data on educational level (69%). The characteristics of 
patients with and without educational level data were similar (Appendix Table 1). 
Individuals with secondary and tertiary education were more likely to be male, to have 
been infected through male-to-male sex, and less likely to have been infected using 
injectable drugs, or to have recently initiated cART (Table 1). There were marked 
differences in the pre-cART CD4 counts, which were highest for those with higher 
levels of education. The prevalence of AIDS at the start of cART was also lower for 
those with higher education. The number and frequency of CD4 count and HIV-RNA 
measurements was similar across educational levels. The proportion of patients without 
completed primary education was considerably higher in Southern Europe than in other 
regions. Loss to follow-up was more common among patients with lower educational 
level.  
Mortality 
Over 132 507 person-years of follow-up, 1081 individuals died. Cumulative mortality 
decreased as educational level increased (p<0.001 log-rank test, Figure 1a). Differences 
in time to death persisted in the confounder-adjusted models; individuals without 
completed primary, primary, and secondary education had higher risks of death than 
those with tertiary education (Table 2a and Appendix table 2 (a) and 2 (b)). We found 
similar mortality gradients when we restricted analyses to those with CD4 >200 
cells/mm
3
 and no AIDS at cART initiation, and those with CD4>350 cells/mm
3
 and no 
AIDS at cART initiation and age ≥25 years (Appendix Table 3). We found no evidence 
of interaction by sex (p=0.582) (Appendix Table 4). Our conclusions were robust to the 
sensitivity analyses for missing educational level, except for the very implausible 
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scenario in which it was assumed that all individuals with missing educational level had 
tertiary education (data not shown).  
Incidence of AIDS or death  
Over 122 765 person-years of follow-up, a new AIDS event or death occurred in 2598 
individuals. Differences in the cumulative incidence of AIDS or death by educational 
level were more marked than for death alone (p<0.001 log-rank test; Figure 1b, Table 
2b). We found no evidence of interaction by sex (p=0.314, data not shown). 
Virological suppression 
At one year after initiating cART, 18 468 individuals (77%) had achieved virological 
suppression. Virological suppression was achieved by 85% of patients with primary 
education, 82% with secondary and 87% with tertiary education, and by 67% of patients 
with incomplete primary education (p <0.001 log-rank test, Figure 1c). The difference 
between groups became smaller over time, and was no longer evident from 10 years 
onwards. When we adjusted for potential confounders (particularly for transmission 
category), those with incomplete primary education and primary education had 20% and 
7% lower risks, respectively, of achieving virological success than those with tertiary 
education (Table 2c).  
Immunological response 
The higher the educational level attained, the higher the CD4 count at cART initiation 
(Table 1) and at each point after cART initiation compared to patients with lower 
educational levels (Figure 2). However, there was no evidence that the rate of CD4 
count recovery differed by educational level in the six months after cART initiation 
(Figure 2, Table 3).   
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DISCUSSION 
HIV-positive patients on combination antiretroviral therapy who had less education had 
higher mortality, higher rates of new AIDS events, and worse virological responses than 
patients under care who had more education. Patients with higher educational 
attainment also had higher CD4 cell counts at cART initiation and maintained higher 
CD4 cell counts over time compared to those less educated. We observed such health 
differentials for an eighteen-year period in eight European countries where access to 
health care and cART is universal, and gradients in mortality were similar for men and 
women. Men dominated in the participating cohorts, but women were over-represented 
in the lower educational strata. The present results build on our previous findings 
showing inequalities in HIV diagnosis and cART initiation by educational level in 
Western Europe (15). The striking differences in mortality and clinical responses to 
cART could not be explained entirely by delayed HIV diagnosis and late cART 
initiation, since differences largely remained after we restricted analyses to those 
initiating cART with CD4 >350 cells/mm
3
 and without previous AIDS diagnoses.  
 
The associations we found between educational level and clinical outcomes are 
probably mediated by material and psychosocial paths already conceptualized by 
various investigators (4-14,19-21), and by the Socioeconomic Inequalities and HIV 
Working Group of COHERE (15). Higher educational level is positively associated 
with choice of employment, higher salaries, and thus greater financial security, though 
the benefits of education on social outcomes persist after adjusting for income (4,19-
21). Educational achievement is also linked to health literacy and the ability to adhere to 
medication, as well as to healthier lifestyles (no smoking, good nutrition, and exercise; 
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22-29). Psychosocial factors such as enhanced cognitive, social, and emotional skills 
and resources that help people cope with stressful life situations are also associated with 
educational accomplishment (27-29). Further, differentials by educational level are 
likely to be linked to causes that predate HIV infection and cART initiation. Indeed, 
excess mortality in disadvantaged populations has been widely reported in the EU, and 
better educated people live longer (1-2). By reducing HIV-related mortality, cART 
makes pre-existing mortality differentials by gender (4, 30-31), ethnicity, and migrant 
status more visible (4,32-33). A recent Danish study reported that elevated mortality 
observed in HIV-positive persons with low education was caused by non-AIDS defining 
lifestyle factors (smoking and alcohol use, 26). The increasing importance of non-AIDS 
morbidity and mortality in HIV-positive populations, secondary to smoking (25-28) and 
other risk-taking behaviours, will increase these socioeconomic gradients if no 
appropriate actions are taken. Finally, physicians may not prescribe optimum treatments 
to patients with lower educational attainment because inadvertently they may believe 
that they are too complex or difficult or to follow for less educated patients. 
 
Poorer virological and immune response in less educated persons probably results from 
poorer adherence to cART, which relies heavily on psychosocial factors including social 
support and health literacy, which in turn are closely associated with educational 
attainment (34-36).  Our results contribute to the body of evidence relating 
socioeconomic status and adherence to HIV medication, albeit through an indirect 
measure of treatment adherence since this is unavailable in the dataset. In a systematic 
review of data published up to 2006, Falagas et al. reported that about one-third of 
studies identified significant associations between educational level and adherence (36). 
More recently, Sobrino et al. have reported that less educated individuals have poorer 
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short-term virological response to cART (9), and similar findings have been reported by 
Gueler et al. when socio-economic status is measured at the neighbourhood level (13). 
Immunological responses also have been reported to be less favourable in less educated 
persons (9,14) due to incomplete HIV viral suppression. We did not find differential 
immunological recovery rates by educational level, though patients with more education 
maintained higher CD4 cell counts throughout follow-up. Monge et al. have reported 
higher resistance to any class of drugs in less educated HIV-positive individuals, and 
attributed it to on-going HIV replication as a result of poor adherence (37). Since the 
efficacy of life-long medication is grounded on adherence, interventions that target 
disadvantaged populations are key to controlling HIV. This could benefit from bringing 
in successful experiences from low-income countries including clinic-linked 
community-based adherence support interventions, which have proven successful in 
South-Africa (38) 
 
A limitation of this study is that it was derived from the selection of patients recruited in 
cohorts who systematically collected information on educational status within the 
COHERE Collaboration. Additionally, as highlighted in previous work by the 
Socioeconomic Inequalities and HIV Working Group for COHERE, educational level is 
insufficient to fully capture socioeconomic status (15). Including other variables such as 
income and occupation may allow us to dissect these complex relationships (4,19-20). 
Analyses of a number of variables that may mediate the effect of educational level on 
outcomes such as smoking, lifestyle, and health-seeking behaviours are also lacking. 
Indeed, understanding the causal relationship between educational level and these 
factors was beyond the scope of our work.  Further, the fact that we did not detect 
significant gender differences may be a consequence of the relatively low number of 
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women and their over-presentation in the lower educational strata.  We hope our 
findings will encourage other researchers to collect information on socioeconomic 
status.. Our findings are robust to the various sensitivity analyses based on different 
assumptions about missing data patterns.  
 
Our analyses are based on the largest cohort collaboration of HIV-positive patients 
within Europe, which allows systematic exploration of gender differences. We found no 
effect of gender on the associations between educational status, and mortality and new 
AIDS events. However, given the relatively lower number of women in HIV cohort 
studies eliciting relevant outcomes by sex is of great interest. In these eight European 
countries, the effect of educational level on HIV diagnosis and cART initiation persists 
after HIV-positive patients are in care and have started on potent and efficacious 
treatments. Educational disadvantage compromises cART effectiveness (15).  
 
Our results have implications for policy intervention and program design at multiple 
levels. They support the argument for sustained educational efforts at the European 
level to improve active citizenship, social cohesion, and health impacting on the macro-
level determinants. They also reinforce the need for proximal down-stream 
interventions on clinical and preventive care among less educated HIV-positive patients 
once they are linked to care to address inequities. If these needs are met in accordance 
with the equity policy framework for Europe Health 2020 (38), the most vulnerable 
groups directly targeted by these interventions will benefit. As Scott-Samuel and Smith 
argue, though, it is unrealistic to expect inequalities to be substantially reduced without 
intensification of upstream policies challenging the  wealth and power status quo of 
neoliberalism (40).   
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Appendix Table 1. Characteristics of patients with known and unknown educational level  
  Known  Unknown  
N (%) 24069 (69%) 10994 (31%) 
AIDS before cART  16% 15% 
Median [IQR] age of cART, years  37 [31,44] 37 [30,44] 
Median [IQR] year of cART  2007 [2002,2010] 2006 [2001,2010] 
Median [IQR] CD4 count 263 [136,380] 260 [127,377] 
Median [IQR] HIV RNA 4.8 [4.1,5.3] 4.8 [4.0,5.3] 
Sex 
21% 23% 
    Female 
    Male 79% 77% 
Transmission category 
  
   Sex between men 46% 39% 
   Sex between men and women 37% 36% 
   Injecting drug use 12% 13% 
    Other/Unknown 5% 11% 
Initial cART combination 
  
   NNRTI 35% 37% 
   PI 49% 46% 
   Other 16% 18% 
Geographical origin 
  
   Europe 68% 71% 
   Other  10% 11% 
   Unknown 22% 18% 
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 Number of CD4 count  12 [6,23] 11 [5,22] 
Mean per patient CD4 count interval (months) 4 [3,5] 4 [3,5] 
Time to last CD4 count (years) 4 [2,8] 4 [2,8] 
Number of HIV RNA 11 [5,21] 11 [5,22] 
Mean per patient HIV RNA interval (months) 4 [3,5] 4 [3,5] 
Time to last HIV RNA (years) 4[2,7] 4 [2,8] 
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 Appendix Table 2.  
 
2 (a) Results from unadjusted and adjusted Cox model for time to death from any-cause after initiation of cAR 
 
 
Characteristics at cART initiation Bivariate analyses  Adjusted analyses  
 Hazard ratio 95% 
confidence 
interval 
P value Hazard 
ratio 
95% 
confidence 
interval 
P value 
Educational level       
   Incompleted basic 2.54 (2.05,3.15)  1.93 (1.54,2.43)  
   Basic 2.04 (1.62,2.56)  1.68 (1.32,2.12)  
   Secondary 1.42 (1.15,1.75)  1.30 (1.05,1.60)  
   Tertiary 1  <0.001 1  <0.001 
Female  Xxx  0.78 (0.66,0.92) 0.003 
Previous AIDS diagnosis    1.33 (1.16,1.54) <0.001 
Risk group       
   Sex between men    1  <0.001 
   Injecting drug use    2.93 (2.44,3.51)  
   Sex between men and women    1.14 (0.96,1.35)  
   Other    1.34 (0.78,2.31)  
   Unknown    1.49 (1.13,1.99)  
Age (10 years)    1.74 (1.65,1.84) <0.001 
Calendar year       
   <2001    1  <0.001  
   2001-2004    0.95 (0.80,1.13)  
   2005-2008    0.76 (0.62,0.93)  
   2009-2013    0.60 (0.46,0.79)  
Geographical Origin       
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    European    1.06 (0.75,1.52) 0.696 
   Non European    1   
   Unknown    0.71 (0.58,1.50)  
CD4 cell count, cells/mm
3 
      
   <200    1  0.004 
   200-349    0.85 (0.73,0.99)  
   350-499    0.67 (0.54,0.84)  
   ≥500    0.89 (0.71,1.12)  
Initial cART combination       
   NNRTI based    1.15 (0.98,1.34) 0.001 
   PI based    1   
   Other    1.39 (1.16,1.67)  
HIV-RNA (log10 scale)    1.04 (0.97,1.10) 0.273 
 
 
 
2 (b) Results from unadjusted and adjusted Cox model for time to a new AIDS event or death from any-cause after initiation of cART. 
 
Characteristics at cART initiation 
Bivariate analyses Adjusted analyses 
Hazard ratio 95% confidence interval 
P 
value 
Hazard ratio 95% confidence interval P value 
Educational level   
 
    
  
   Incompleted basic 2.19 (1.91,2.50)   1.60 (1.39,1.85)  
   Basic 2.04 (1.62,2.56)   1.51 (1.30,1.75)  
   Secondary 1.35 (1.19,1.54)   1.21 (1.06,1.38)  
   Tertiary 1 
 
<0.001 1 
 
<0.001 
Female   
 
  0.9 (0.81,1.00) 0.052 
Previous AIDS diagnosis   
 
  1.33 (1.22,1.46) <0.001 
Risk group   
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    Sex between men   
 
  1 
 
<0.001 
   Injecting drug use   
 
  1.84 (1.63,2.07)  
   Sex between men and women   
 
  1.12 (1.01,1.25)  
   Other   
 
  1.20 (0.83,1.75)  
   Unknown   
 
  1.29 (1.06,1.56)  
Age (10 years)   
 
  1.74 (1.65,1.84) <0.001 
Calendar year   
 
    
  
   <2001   
 
  1 
 
<0.001  
   2001-2004   
 
  0.85 (0.76,0.95)  
   2005-2008   
 
  0.65 (0.58,0.74)  
   2009-2013   
 
  0.57 (0.49,0.66)  
Geographical Origin   
 
    
  
   European   
 
  0.89 (0.74,1.06) 0.058 
   Non European   
 
  1 
  
   Unknown   
 
  0.72 (0.55,0.95) 
 
CD4 cell count, cells/mm3   
 
    
  
   <200   
 
  1 
 
<0.001  
   200-349   
 
  0.58 (0.53,0.65) 
 
   350-499   
 
  0.47 (0.41,0.55) 
 
   ≥500   
 
  0.52 (0.44,0.61) 
 
Initial cART combination   
 
    
  
   NNRTI based   
 
  1.12 (1.02,1.24) <0.001  
   PI based   
 
  1 
  
   Other   
 
  1.36 (1.21,1.52) 
 
HIV-RNA (log10 scale)       1.14 (1.09,1.19) 0.273 
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 Appendix Table 3. Adjusted hazard ratios for sensitivity analyses restricting to patients with i) CD4>200 cells/mm3 and no AIDS at cART 
initiation, ii) with CD4>350 cells/mm3 and no AIDS at cART initiation and iii) age ≥25 years   
 
Educational level 
CD4>200 and no AIDS (N 
14528)  
CD4>350 and no AIDS (N 7028)  Age ≥ 25 (N=22922) 
Incompleted basic 2.38 (1.63,3.50)  1.79 (1.00,3.17)  1.94 (1.54,2.44) 
Basic 2.04 (1.39,3.00) 2.14 (1.23,3.71) 1.67 (1.31,2.12) 
Secondary 1.70 (1.21,2.35) 1.36 (0.83,2.22) 1.29 (1.05,1.60) 
Tertiary 1 1 1 
  p<0.001 p 0.039  p<0.001 
 
 
*Models adjusted for sex, risk group, previous AIDS diagnosis, calendar period, initial cART combination, geographical origin, CD4 count, age 
and HIV-RNA at cART initiation 
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 Appendix Table 4. Assessing the role of gender as an effect modifier. Unadjusted and adjusted* time ratios of mortality for males and females 
and results from the likelihood ratio test to test the interaction by gender.  
 
 
Unadjusted Adjusted 
Educational level Male (N=18906) Female (N=5163) Male (N=18906) Female (N=5163) 
Incompleted basic 2.87  (2.27,3.62) 3.04 (1.55,5.94) 1.89  (1.47,2.43) 2.84 (1.43,5.66) 
Basic 2.25 (1.75,2.89) 2.36 (1.18,4.70) 1.71 (1.32,2.21) 2.17 (1.07,4.38) 
Secondary 1.40 (1.12,1.75) 2.02 (1.03,3.96) 1.27 (1.01,1.58) 1.91 (0.97,3.78) 
Tertiary 1 1 1 1 
Likelihood ratio test 
 for interaction 
p 0.352 p 0.566 
*Models adjusted for risk group, previous AIDS diagnosis, calendar period, initial cART combination, geographical origin, CD4 count, age and 
HIV-RNA at cART initiation and stratified by cohort. 
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Figure 1. Cumulative incidence of mortality (a), AIDS or mortality (b), and virological 
success (c) after initiation of combined antiretroviral therapy (cART) by educational 
level.  
 
a. 
 
b. 
 
c. 
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Figure 2. Estimated of in CD4 count after cART initation from a piecewise linear mixed 
model. Baseline individual: no AIDS, male, MSM, cART initiation <2001, European 
origin, NNRTI-based initial cART combination, age 37 years and viral load of 5.4 log 
copies/mL. 
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Table 1  Patient characteristics at cART initiation, overall, and by educational level 
 
  Incompleted primary Primary Secondary Tertiary Overall 
N (%) 5719 (9%) 4999 (32%) 7945 (44%) 5406 (15%) 24069 (100%) 
Sex        
    Female 1851 (32%) 1307 (26%) 1462 (18%) 543 (10%) 5163 (21%) 
    Male 3868 (68%) 3692 (74%) 6483 (82%) 4863 (90%) 18906 (79%) 
Transmission category        
   Sex between men 1057 (18%) 1800 (36%) 4275 (54%) 3919 (73%) 11051 (46%) 
   Sex between men and women 2938 (51%) 2242 (45%) 2674 (37%) 1123 (21%) 8977 (37%) 
   Injecting drug use 1413 (25%) 729 (15%) 647 (8%) 118 (2%) 2907 (12%) 
   Other/Unknown 311 (5%) 228 (5%) 349 (4%) 246 (5%) 1134 (5%) 
Median [IQR] age of cART, years  37 [31,45] 37 [31,45] 37 [31,44] 37 [31,43] 37 [31,44] 
Median [IQR] year of cART  2005 [2001,2009] 
2007 
[2003,2010] 
2007 
[2003,2010] 
2008 
[2004,2011] 
2007 
[2002,2010] 
Geographical origin        
   Europe 4466 (78%) 3384 (68%) 5132 (65%) 3419 (63%) 16401 (68%) 
   Other  514 (9%) 667 (13%) 694 (9%) 517 (10%) 2392 (10%) 
   Unknown 739 (13%) 948 (19%) 2119 (27%) 1470 (27%) 5276 (22%) 
AIDS before cART  1235 (22%) 746 (15%) 1153 (15%) 600 (11%) 3734(16%) 
Median [IQR] CD4 count 220 [90,343] 259 [136,375] 267 [140,382] 300 [189,411] 263 [136,380] 
Number of CD4 count per patient 13 [6,24] 12 [6,22] 12 [6,23] 11 [5,21] 12 [6,22] 
Mean CD4 count interval per patient 
(months) 
4 [3,6] 4 [3,5] 4 [3,5] 4 (3,5) 4 [3,5] 
Median [IQR] HIV RNA 4.9[4.2,5,4] 4.8 [4.1,5.3] 4.8 [4.2,5.3] 4.8 [4.2,5.3] 4.8 [4.2,5.3] 
Number of HIV RNA 12 [6,23] 11 [6,20] 11 [5,21] 10 [5,19] 11 [6,21] 
Mean per patient HIV RNA interval 
(months) 
4 [3,6] 4 [3,5] 4 [3,57] 4 [3,5] 4 [3,5] 
  
Initial cART combination        
   NNRTI 2096 (37%) 1853 (37%) 2744 (35%) 1735 (32%) 8428 (35%) 
   PI 2768 (48%) 2218 (44%) 3960 (50%) 2763 (51%) 11709 (49%) 
   Other 855 (15%) 928 (19%) 1241 (16%) 908 (17%) 3932 (16%) 
Cohort geographical area        
   Greece, Italy, Spain 4748 (83%) 2855 (57%) 5574 (70%) 3373 (62%) 16550 (69%) 
   Austria, Germany, Netherlands, 
   Switzerland 
971 (17%) 2144 (43%) 2371 (30%) 2033 (38%) 7519 (31%) 
Median follow-up, years 5.2  4.1 4.4 3.8 4.4 
      
Proportion lost to follow-up 1486 (28%) 1006 (20%) 1427 (18%) 893 (17%) 4812 (21%) 
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Table 2.  Differences in mortality, new AIDS event/death, virological suppression from cART initiation according to educational level 
 
 
Educational level a)                                Mortality b)          New AIDS event or mortality c)       Virological success 
Incompleted primary 1.93 (1.54,2.43)       1.60 (1.39, 1.85)  0.80 (0.76,0.84) 
Primary 1.68 (1.32, 2.12) 1.51 (1.30, 1.75) 0.93 (0.89,0.97) 
Secondary 1.30 (1.05,1.60) 1.21 (1.06, 1.38) 0.97 (0.94,1.01) 
Tertiary 1 1 1 
  p<0.001 p<0.001  p<0.001 
 
*Cox models adjusted for sex, risk group, previous AIDS diagnosis, calendar period, initial cART combination, geographical origin, CD4 count, age and HIV-RNA at cART 
initiation and stratified by cohort. 
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Table 3.  Estimates of change in square root CD4 count after initiation of combined antiretroviral therapy (cART) from a piecewise linear mixed 
model.  
 
 Estimate (95% CI) P 
CD4 count at time 0 for baseline* patient with tertiary education 21.96 (21.49, 22.42) <0.001 
   Incompleted primary  -1.24 (-1.50, -0.97)  
   Primary -0.38 (-0.63, -0.12)  
   Secondary -0.71 (-0.94, -0.48)  
   Tertiary ref   <0.001 
Annual rate of increase in the first 6 months for baseline patient with tertiary education 6.67 (6.37, 6.96) <0.001 
   Incompleted primary -0.14 (-0.57, 0.30)  
   Primary -0.41 (-0.83, 0.02)  
   Secondary 0.25 (-0.13, 0.64)  
   Tertiary ref   0.111 
Annual rate of increase after 6 months for tertiary education 0.80 (0.76, 0.85) <0.001 
   Incompleted primary 0.00 (-0.05, 0.06)  
   Primary -0.04 (-0.10, 0.02)  
   Secondary 0.05 (-0.01, 0.10)  
   Tertiary ref   0.115 
Pre-cART AIDS -3.62 (-3.79, -3.44) <0.001 
   Sex     
   Male ref    
Female 0.39 (0.21, 0.57) <0.001 
Mode of exposure     
   Sex between men ref   <0.001 
   Injecting drug use -2.76 (-2.99, -2.54)  
   Sex between men and women -1.43 (-1.60, -1.26)  
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   Other -1.16 (-1.82, -0.50)  
   Unknown -1.29 (-1.63, -0.96)  
Age at cART, 10 year -0.56 (-0.62, -0.50) <0.001 
Year at cART initiation     
   <2001 -1.58 (-1.79, -1.38) <0.001 
   2001-2004 -2.16 (-2.36, -1.97)  
   2005-2008 -1.58 (-1.74, -1.42)  
   2009-2013 ref    
Geographical origin     
   European ref   <0.001 
   Non -European -1.03 (-1.25, -0.81)  
   Other  -0.63 (-0.79, -0.47)  
Initial cART combination     
   NNRTI ref   0.024 
   PI -0.21 (-0.36, -0.06)  
   Other  -0.05 (-0.23, 0.13)  
Viral load (log10 scale) -0.32 (-0.38, -0.26) <0.001 
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